Global Outlook for the Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022 – Rising Number of Patients Opting for Chemotherapy – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Chemotherapy-induced Neutropenia Therapeutics Market 2018-2022”

report has been added to ResearchAndMarkets.com’s
offering.

The Global Chemotherapy-Induced Neutropenia Therapeutics Market to grow
at a CAGR of 5.52% during the period 2018-2022.

The report has been prepared based on an in-depth market analysis with
inputs from industry experts. The report covers the market landscape and
its growth prospects over the coming years. The report also includes a
discussion of the key vendors operating in this market.

One trend affecting this market is increase in global awareness about
cancer treatments. Awareness about cancer treatments and cancer related
issues across the US has increased primarily because of the continuing
efforts of different organizations.

According to the report, one driver influencing this market is the
rising number of patients opting for chemotherapy. The increasing use of
chemotherapy and its associated risks in affecting immunity due to
neutropenia, coupled with growing patient population, generate the
demand for CIN therapeutics.

Further, the report states that one challenge affecting this market is
the high cost of treatment. Through chemotherapy is an effective
treatment for cancer, the risks associated with it, such as CIN, can
lead to increase in hospital visits and longer hospital stays.

Key Vendors

  • Amgen
  • Intas Pharmaceuticals
  • Novartis
  • Partner Therapeutics
  • Teva Pharmaceuticals Industries

Key Topics Covered

1. Executive Summary

2. Scope of the Report

3. Research Methodology

4. Market Landscape

5. Market Sizing

6. Five Forces Analysis

7. Market Segmentation by Procedure

8. Customer Landscape

9. Regional Landscape

10. Decision Framework

11. Drivers and Challenges

12. Market Trends

13. Vendor Landscape

14. Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/l63fmx/global_outlook?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs
, Infectious
Diseases Drugs